MA50979B1 - Application de totarol et composition pharmaceutique contenant du totarol - Google Patents

Application de totarol et composition pharmaceutique contenant du totarol

Info

Publication number
MA50979B1
MA50979B1 MA50979A MA50979A MA50979B1 MA 50979 B1 MA50979 B1 MA 50979B1 MA 50979 A MA50979 A MA 50979A MA 50979 A MA50979 A MA 50979A MA 50979 B1 MA50979 B1 MA 50979B1
Authority
MA
Morocco
Prior art keywords
totarol
treatment
weight
parts
pharmaceutical composition
Prior art date
Application number
MA50979A
Other languages
English (en)
Other versions
MA50979A (fr
Inventor
Mariusz Cieciara
Artur Wrzosek
Original Assignee
Emergopharm Sp Z O O Sp K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergopharm Sp Z O O Sp K filed Critical Emergopharm Sp Z O O Sp K
Publication of MA50979A publication Critical patent/MA50979A/fr
Publication of MA50979B1 publication Critical patent/MA50979B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'application de totarol pour la production d'une préparation pour le traitement d'inflammations de la membrane muqueuse vaginale d'origine bactérienne, pour le soulagement de symptômes dans un tel traitement et pour la prophylaxie et la prévention de récidives de telles inflammations. L'invention concerne également une composition pharmaceutique pour le traitement d'inflammations de la membrane muqueuse vaginale d'origine bactérienne, pour le soulagement de symptômes dans un tel traitement et pour la prophylaxie et la prévention de récidives de telles inflammations, la composition contenant de 75 à 95 parties en poids d'un dérivé de cellulose, de 0,5 à 5 parties en poids d'acide lactique, de 0,5 à 5 parties en poids d'un polymère basique, le rapport stœchiométrique entre l'acide lactique et le polymère basique étant compris dans la plage de 1:1 à 8:1 et comprenant du totarol en une quantité de 0,001 à 5 parties en poids en tant que principe actif.
MA50979A 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol MA50979B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL422140A PL236429B1 (pl) 2017-07-06 2017-07-06 Zastosowanie totarolu do wytwarzania preparatu do leczenia bakteryjnego zakażenia pochwy i kompozycja farmaceutyczna do zastosowania w leczeniu stanów zapalnych pochwy o podłożu bakteryjnym
PCT/PL2018/000066 WO2019009739A1 (fr) 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol

Publications (2)

Publication Number Publication Date
MA50979A MA50979A (fr) 2020-10-14
MA50979B1 true MA50979B1 (fr) 2022-11-30

Family

ID=63518002

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050980A MA50980A (fr) 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol
MA50979A MA50979B1 (fr) 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA050980A MA50980A (fr) 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol

Country Status (18)

Country Link
US (1) US11534412B2 (fr)
EP (1) EP3648751B1 (fr)
KR (1) KR20200024921A (fr)
CA (1) CA3066602C (fr)
CL (1) CL2019003720A1 (fr)
DK (1) DK3648751T3 (fr)
ES (1) ES2929646T3 (fr)
HR (1) HRP20221338T1 (fr)
HU (1) HUE060300T2 (fr)
IL (1) IL271875B2 (fr)
LT (1) LT3648751T (fr)
MA (2) MA50980A (fr)
PL (1) PL236429B1 (fr)
PT (1) PT3648751T (fr)
RS (1) RS63728B1 (fr)
SI (1) SI3648751T1 (fr)
UA (1) UA126031C2 (fr)
WO (1) WO2019009739A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948891A (zh) * 2021-06-07 2022-08-30 南通联亚药业股份有限公司 药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL107491B1 (pl) 1977-10-29 1980-02-29 Przemyslowy Instytut Automatyk Czujnik dwustrunowy do pomiaru malych przesuniec
PL201869A1 (pl) 1977-10-29 1979-05-21 Inst Przemyslu Organiczego Sposob wytwarzania masy kablowej odpornej na dzialanie termitow
JP2700071B2 (ja) 1988-06-10 1998-01-19 株式会社資生堂 抗菌剤及びそれを用いた皮膚外用剤、口腔用組成物
PL166898B1 (pl) 1992-02-13 1995-06-30 Akad Medyczna Sposób wytwarzania kompleksu metylocelulozy z kwasem mlekowym
US6534548B1 (en) * 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
PL194437B1 (pl) 2002-06-05 2007-05-31 Akademia Medyczna Im Piastow S Sposób wytwarzania kompleksu na bazie kwasu mlekowego
NZ530834A (en) 2004-01-28 2007-06-29 Owen John Catchpole Near-critical extraction of totarol and/or a product containing totarol
US20090312279A1 (en) * 2005-12-23 2009-12-17 Sterilex Technologies, Llc Antimicrobial compositions
EP1925302A1 (fr) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Composition diététique où pharmaceutique contentant de diterpène tricycliques et leurs dérivés pour le traitment de la dépression
EP1925301A1 (fr) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Utilisation de diterpènes tricycliques et de leurs dérivés pour le traitement et la prévention d'affections inflammatoires et/ou des articulations
JP5471335B2 (ja) * 2009-11-17 2014-04-16 ライオン株式会社 口腔バイオフィルム殺菌剤
CA2859519C (fr) * 2011-12-15 2016-08-16 Colgate-Palmolive Company Composition antibacterienne a base de thymol et de totarol
WO2014137231A2 (fr) 2013-03-07 2014-09-12 T2G Biotechnology Limited Formulations d'extrait de totarol et leurs utilisations
DE102013108870A1 (de) * 2013-08-16 2015-02-19 Aimecs Gmbh Mittel zur Reinigung und zum Schutz von technischen Oberflächen
CN104027260A (zh) 2014-06-20 2014-09-10 广州薇美姿个人护理用品有限公司 一种含有桃柘酚的口腔护理用品
CN104688810A (zh) 2014-12-29 2015-06-10 昆明皕凯科技有限公司 一种基于天然植物原料的抗菌组合物及其应用
CN106581687A (zh) * 2016-12-22 2017-04-26 吉林大学 以乳清蛋白为基质的桃柁酚抗菌纳米水凝胶及其制备方法

Also Published As

Publication number Publication date
UA126031C2 (uk) 2022-08-03
CA3066602C (fr) 2024-01-02
RU2020104832A (ru) 2021-08-06
MA50980A (fr) 2020-10-14
PL422140A1 (pl) 2019-01-14
HRP20221338T1 (hr) 2022-12-23
DK3648751T3 (da) 2022-11-21
MA50979A (fr) 2020-10-14
IL271875B2 (en) 2023-02-01
US20200289429A1 (en) 2020-09-17
EP3648751A1 (fr) 2020-05-13
LT3648751T (lt) 2022-12-12
PL236429B1 (pl) 2021-01-11
KR20200024921A (ko) 2020-03-09
PT3648751T (pt) 2022-10-20
BR112019027839A2 (pt) 2020-07-07
IL271875A (en) 2020-02-27
RU2020104832A3 (fr) 2021-10-08
SI3648751T1 (sl) 2023-03-31
WO2019009739A4 (fr) 2019-02-28
CL2019003720A1 (es) 2020-05-22
EP3648751B1 (fr) 2022-09-28
ES2929646T3 (es) 2022-12-01
US11534412B2 (en) 2022-12-27
IL271875B (en) 2022-10-01
HUE060300T2 (hu) 2023-02-28
RS63728B1 (sr) 2022-12-30
CA3066602A1 (fr) 2019-01-10
WO2019009739A1 (fr) 2019-01-10

Similar Documents

Publication Publication Date Title
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA58700B1 (fr) Souche de cutibacterium acnes et utilisations médicales associées
MA51612A (fr) Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant
MA56038B1 (fr) Inhibiteurs à petite molécule de kinase induisant nf-kb
MA53086B1 (fr) Thiophènecarboxamides substitués et analogues comme agents antibactériens
AU2016209550A1 (en) Novel iodophor composition and methods of use
WO2016063432A1 (fr) Procédé de lutte contre la saprolegnia dans de l'eau de culture
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
MA62917A1 (fr) Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens
MA50979B1 (fr) Application de totarol et composition pharmaceutique contenant du totarol
NO323049B1 (no) Desinfiseringssammensetning
MA46563B1 (fr) Compositions dispersibles
FR2358398A1 (fr) Medicament a base du sel cereux de la sulfadiazine
CA2376121C (fr) Solution de xylometazoline et d'oxymetazoline stable
Hopkins et al. Fungistatic agents for treatment of dermatophytosis
MX2023012704A (es) Cepas bacterianas que tienen actividad fungicida, composiciones que las comprenden y uso de estas.
FR3126991B1 (fr) Souche bactérienne dans la prévention et/ou le traitement de pathologies inflammatoires
CN101222939A (zh) 眼科用防腐组合物
CN107018999A (zh) 一种温和稳定的手机杀菌湿纸巾及其应用
FR3111817B1 (fr) Extrait d’Hibiscus sabdariffa et son utilisation pour améliorer la fonction barrière, et favoriser l’hydratation et la desquamation de la peau
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
Veraldi Rapid relief of intertrigo‐associated pruritus due to Candida albicans with isoconazole nitrate and diflucortolone valerate combination therapy
EA202192541A1 (ru) Фармацевтическая композиция для местного применения в виде водного геля, содержащая, по меньшей мере, амитриптилин
MA71282A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une néphropathie et/ou du diabète sucré, comprenant de l'énavogliflozine